MannKind completes phase 1 trial of nintedanib DPI for pulmonary fibrotic diseases: Danbury, Connecticut Tuesday, November 5, 2024, 16:00 Hrs [IST] MannKind Corporation, a company ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for third ...

A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the ...

Under the terms of the agreement, Surrozen will provide antibody discovery services for a period of up to two years. TCGFB will own all TGF-β product related intellectual property. In exchange for ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

Research collaboration to leverage Surrozen's antibody research capabilities and expertise to discover a potential first in class <a target=_blank ...

The Crown Prince and Princess (left) were informed in advance that their stepson and son was going to be arrested following ...

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of ...